Conceptos Categóricos

Crónicas de autores

Alexandre González-Rodríguez *

Autor invitado por SIIC

El presente estudio trata de resolver la controversia en relación con las dosis antipsicóticas requeridas y las tasas de respuesta antipsicótica en el trastorno delirante.

ESTUDIO COMPARATIVO DE LA RESPUESTA ANTIPSICÓTICA EN PACIENTES CON TRASTORNO DELIRANTE Y ESQUIZOFRENIA

El trastorno delirante ha sido considerado un trastorno difícil de tratar y resistente al tratamiento. El presente estudio muestra tasas de respuesta antipsicótica similares en pacientes con trastorno delirante y esquizofrenia, y dosis antipsicóticas requeridas similares.

*Alexandre González-Rodríguez
describe para SIIC los aspectos relevantes de su trabajo
RESPUESTA ANTIPSICÓTICA EN TRASTORNO DELIRANTE Y ESQUIZOFRENIA: ESTUDIO PROSPECTIVO DE COHORTES
Actas Españolas de Psiquiatría,
44(4):125-135 Jul, 2016

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Unidad de Esquizofrenia Clínic. Instituto Clínic de Neurociencias. Hospital Clínic de Barcelona. Cibersam, Idibaps. Barcelona, España, Barcelona, España
Imprimir nota
Referencias bibliográficas
1. Kendler KS. Demography of paranoid psychosis (delusional disorder): a review and comparison with schizophrenia and affective illness. Arch Gen Psychiatry 39(8):890-902, 1982.
2. Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry 51(2):114-9, 2006.
3. Munro A, Mok H. An overview of treatment in paranoia/delusional disorder. Can J Psychiatry 40(10):616-22, 1995.
4. Lepping P, Russell I, Freudenmann RW. Antipsychotic treatment of primary delusional parasitosis: systematic review. Br J Psychiatry 191:198-205, 2007.
5. Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. J Clin Psychopharmacol 28(5):500-8, 2008.
6. Huber M, Lepping P, Pycha R, Karner M, Schwitzer J, Freudenmann RW. Delusional infestation: treatment outcome with antipsychotics in 17 consecutive patients (using standardized reporting criteria). Gen Hosp Psychiatry 33(6):604-11, 2011.
7. Mews MR, Quante A. Comparative efficacy and acceptability of existing pharmacotherapies for delusional disorder: a retrospective case series and review of the literature. J Clin Psychopharmacol 33(4):512-9, 2013.
8. González Rodríguez A, Molina Andreu O, Imaz Gurrutxaga ML, Catalan Campos R, Bernardo Arroyo M. A descriptive retrospective study of the treatment and outpatient service use in a clinical group of delusional disorder patients. Rev Psiquiatr Salud Ment 7(2):64-71, 2014.
9. Roudsari MJ, Jinsoo Chun J, Manschreck, TC. Current treatments for delusional disorder. Curr Treat Options Psych 2:151-67, 2015.
10. Skelton M, Khokhar WA, Thacker SP. Treatments for delusional disorder. Schizophr Bull 41(5):1010-2, 2015.
11. Skelton M, Khokhar WA, Thacker SP. Treatments for delusional disorder. Cochrane Database Syst Rev 5:CD009785, 2015.
12. Serretti A, Lattuada E, Cusin C, Smeraldi E. Factor analysis of delusional disorder symptomatology. Compr Psychiatry 40(2):143-7, 1999.
13. De Portugal E, González N, Del Amo V, Haro JM, Díaz Caneja CM, Luna del Castillo JD, et al. Empirical redefinition of delusional disorder and its phenomenology: the DELIREMP study. Compr Psychiatry 54(3):243-55, 2013.
14. Muñoz Negro JE, Ibanez Casas I, De Portugal E, Ochoa S, Dolz M, Haro JM, et al. A dimensional comparison between delusional disorder, schizophrenia and schizoaffective disorder. Schizophr Res 169(1-3):248-54, 2015.
15. De Portugal E, González N, Vilaplana M, Haro JM, Usall J, Cervilla JA. An empirical study of psychosocial and clinical correlates of delusional disorder: the DELIREMP study. Rev Psiquiatr Salud Ment 2(2):72-82, 2009.
16. González Rodríguez A, Molina Andreu O, Penadés R, Bernardo M, Catalán R. Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. Int Clin Psychopharmacol 29(3):177-80, 2014.
17. González Rodríguez A, Molina Andreu O, Penadés R, Bernardo M, Catalán R. Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model. J Clin Psychopharmacol 35(2):201-2, 2015.
18. Marneros A, Pillmann F, Wustmann T. Delusional disorders--are they simply paranoid schizophrenia? Schizophr Bull 38(3):561-8, 2012.
19. Grover S, Nehra R, Bhateja G, Kulhara P, Kumar S. A comparative study of cognitive deficits in patients with delusional disorder and paranoid schizophrenia. Ind Psychiatry J 20(2):107-14, 2011.
20. Ibanez-Casas I, De Portugal E, Gonzalez N, McKenney KA, Haro JM, Usall J, et al. Deficits in executive and memory processes in delusional disorder: a case-control study. PLoS One 8(7):e67341, 2013.
21. Hui CL, Lee EH, Chang WC, Chan SK, Lin J, Xu JQ, et al. Delusional disorder and schizophrenia: a comparison of the neurocognitive and clinical characteristics in first-episode patients. Psychol Med 1-11, 2015.
22. Ibanez Casas I, Cervilla JA. Neuropsychological research in delusional disorder: a comprehensive review. Psychopathology 45(2):78-95, 2012.
23. Maina G, Albert U, Badà A, Bogetto F. Occurrence and clinical correlates of psychiatric co-morbidity in delusional disorder. Eur Psychiatry 16(4):222-8, 2001.
24. De Portugal E, Martínez C, González N, Del Amo V, Haro JM, Cervilla JA. Clinical and cognitive correlates of psychiatric comorbidity in delusional disorder outpatients. Aust N Z J Psychiatry 45(5):416-25, 2011.
25. Ahmed A, Bewley A. Delusional infestation and patient adherence to treatment: an observational study. Br J Dermatol 169(3):607-10, 2013.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV-TR. Washington, 2000.
27. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, et al. Dose equivalents for second-generation antipsychotic drugs: The classical mean dose method. Schizophr Bull pii: sbv037, 2015.
28. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS. The Positive and Negative Syndrome Scale - Spanish adaptation. J Nerv Ment Dis 178:510-7, 1990.
29. Garcia Portilla MP, Saiz PA, Bousoño M, Bascaran MT, Guzmán Quilo C, Bobes J et al. Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. Rev Psiquiatr Salud Ment 4(1):9-18, 2011.
30. Apiquian R, Elena Ulloa R, Herrera-Estrella M, Moreno-Gómez A, Erosa S, Contreras V, Nicolini H. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophr Res 112(1-3):181-6, 2009.
31. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-71, 1976.
32. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168(12):1266-77, 2011.
33. Van der Gaag M, Hoffman T, Remijsen M, Hijman R, De Haan L, Van Meijel B, et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 85(1-3):280-7, 2006.
34. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115-25, 2010.
35. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13(5):318-78, 2012.
36. Penadés R, Pujol N, Catalán R, Massana G, Rametti G, García Rizo C, et al. Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study. Biol Psychiatry 73(10):1015-23, 2013.
37. Rabinowitz J, Mehnert A, Eerdekens M. To what extent do the PANSS and CGI-S overlap? J Clin Psychopharmacol 26(3):303-7, 2006.
38. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 98(1-3):318-22, 2008.
Otros artículos de Alexandre González-Rodríguez

González Rodríguez A, Molina Andreu O, Penadés R, Bernardo M, Catalán R. Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model. Journal of Clinical Psychopharmacology 35(2):201-2, 2015.
González Rodríguez A, Catalán R, Penadés R, Ruiz V, Torra M, Seeman, MV, Bernardo M. Antipsychotic response worsens with postmenopausal duration in women with schizophrenia. Journal of Clinical Psychopharmacology. En prensa.
Molina Andreu O, González Rodríguez A, Pons Villanueva A, Penadés R, Catalán R, Bernardo M. Awareness of illness and suicidal behavior in delusional disorder patients. Archives of Clinical Psychiatry 41(6):156-8, 2014.
González Rodríguez A, Molina Andreu O, Penadés R, Catalán R, Bernardo M. Reproductive variables and gynaecological service use in delusional disorder outpatients. Revista de Psiquiatría y Salud Mental 8(2):92-6, 2015.
González Rodríguez A, Molina Andreu O, Penadés R, Bernardo M, Catalán R. Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. International Clinical Psychopharmacology 29(3):177-80, 2014.
González Rodríguez A, Molina Andreu O, Navarro V, Gastó C, Penadés R, Catalán R. Delusional disorder: no gender differences in age at onset, suicidal ideation, or suicidal behavior. Revista Brasileira de Psiquiatria 36(2):119-24, 2014.
González Rodríguez A, Molina Andreu O, Penadés R, Catalán R, Bernardo M. Clinical significance of suicidal behavior in delusional disorder: a 44 case series study. Medicina Clínica (Barc) 142(7):299-302, 2014.
González Rodríguez A, Molina Andreu O, Imaz ML, Catalán R, Bernardo M. A descriptive retrospective study on treatment and outpatient service use in a clinical group of delusional disorder patients. Revista de Psiquiatría y Salud Mental 7(2):64-71, 2014.
González Rodríguez A, Studerus E, Spitz A, Rapp C, Bugra H, Aston J, Borgwardt S, Riecher-Rössler A. Gender differences in the psychopathology of emerging psychosis. Israel Journal of Psychiatry and Related Sciences 51(2):85-92, 2014.
González Rodríguez A, Molina Andreu O, Navarro V, Gastó C, Penadés R, Catalán R. Delusional disorder: an overview of affective symptoms and antidepressant use. The European Journal of Psychiatry 27(4):265-276, 2013.

Para comunicarse con Alexandre González-Rodríguez mencionar a SIIC como referencia:
alexgonzalezrguez@gmail.com

Autor invitado
8 de septiembre, 2016
Descripción aprobada
14 de septiembre, 2016
Reedición siicsalud
29 de enero, 2021

Acerca del trabajo completo
ESTUDIO COMPARATIVO DE LA RESPUESTA ANTIPSICÓTICA EN PACIENTES CON TRASTORNO DELIRANTE Y ESQUIZOFRENIA

Título original en castellano
RESPUESTA ANTIPSICOTICA EN TRASTORNO DELIRANTE Y ESQUIZOFRENIA: ESTUDIO PROSPECTIVO DE COHORTES.

Autor


Acceso a la fuente original
Actas Españolas de Psiquiatría
http://www.fundacionlopezibor.es

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317
-->